NCT02425579 - Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions

Acute Respiratory Distress Syndrome (ARDS)

Interventions

DRUG

Inhaled Carbon Monoxide at 100ppm (4 participants)

Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days

DRUG

Placebo for Inhaled Carbon Monoxide at 100ppm (2 participants)

Inhaled Medical Air for up to 90 minutes daily for 5 days

DRUG

Inhaled Carbon Monoxide at 200ppm (4 participants)

Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days

DRUG

Placebo for Inhaled Carbon Monoxide at 200ppm (2 participants)

Inhaled Medical Air for up to 90 minutes daily for 5 days

Trial Locations (4)

Weill Cornell Medical College/NewYork-Presbyterian, New York

Duke Univesity Hospital, Durham

Massachusetts General Hospital, Boston

Brigham and Women's Hospital, Boston